Positions

Overview

  • CF researcher

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis.  Journal of Cystic Fibrosis.  20:612-617. 2021
    2020 Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis.  Journal of Cystic Fibrosis.  19:783-790. 2020
    2020 Tobacco smoke exposure in pediatric cystic fibrosis: A qualitative study of clinician and caregiver perspectives on smoking cessation.  Pediatric Pulmonology.  55:2330-2340. 2020
    2020 Non-invasive forced oscillometry to quantify respiratory mechanics in term neonates.  Pediatric Research.  88:293-299. 2020
    2019 An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB).  Journal of Cystic Fibrosis.  18:838-843. 2019
    2019 Area deprivation as a risk factor for methicillin-resistant Staphylococcus aureus infection in pediatric cystic fibrosis 2019
    2019 CFTR dysfunction increases endoglin and TGF-β signaling in airway epithelia.  Physiological Reports.  7. 2019
    2019 Objective versus self-reported adherence to airway clearance therapy in cystic fibrosis 2019
    2019 Reply to Finotti et al..  American Journal of Respiratory and Critical Care Medicine.  199:1444-1445. 2019
    2018 MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway Epithelia.  American Journal of Respiratory and Critical Care Medicine.  197:632-643. 2018
    2017 Airway microbiota across age and disease spectrum in cystic fibrosis..  European Respiratory Journal.  50. 2017
    2017 Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: Analysis of oxidative stress in lung fibroblasts.  Bone Marrow Transplantation.  52:765-768. 2017
    2017 Effect of prenatal versus postnatal Vitamin D deficiency on pulmonary structure and function in mice.  American Journal of Respiratory Cell and Molecular Biology.  56:383-392. 2017
    2016 Constrictive bronchiolitis in cystic fibrosis adolescents with refractory pulmonary decline.  Annals of the American Thoracic Society.  13:2174-2183. 2016
    2016 Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening.  Pediatric Pulmonology.  51:1168-1176. 2016
    2016 Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study 2016
    2016 Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.  Journal of Cystic Fibrosis.  15:67-73. 2016
    2015 Adherence to airway clearance therapy in pediatric cystic fibrosis: Socioeconomic factors and respiratory outcomes.  Pediatric Pulmonology.  50:1244-1252. 2015
    2015 Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis.  Pediatric Nephrology.  30:1879-1888. 2015
    2014 Acute Kidney Injury in Hospitalized Children With Cystic Fibrosis.  Journal of Clinical Pediatric Nephrology.  2:5-5. 2014
    2014 TGF-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia.  PLoS ONE.  9. 2014
    2014 Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patients.  Clinical and Translational Science.  7:336-341. 2014
    2013 Erratum: Myofibroblast differentiation and enhanced Tgf-B signaling in cystic fibrosis lung disease (PLoS ONE (2013) 8 (8)).  PLoS ONE.  8. 2013
    2013 IP-10 Is a Potential Biomarker of Cystic Fibrosis Acute Pulmonary Exacerbations.  PLoS ONE.  8. 2013
    2013 Myofibroblast Differentiation and Enhanced Tgf-B Signaling in Cystic Fibrosis Lung Disease.  PLoS ONE.  8. 2013
    2013 Crohn's disease with pulmonary manifestations in children: 2 case reports and review of the literature.  Journal of Crohn's and Colitis.  7. 2013
    2011 Plasma TGF-β1 in pediatric cystic fibrosis: Potential biomarker of lung disease and response to therapy.  Pediatric Pulmonology.  46:688-695. 2011
    2010 Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas.  Pediatric Pulmonology.  45:281-290. 2010
    2009 Transforming growth factor-β1 in bronchoalveolar lavage fluid from children with cystic fibrosis.  Pediatric Pulmonology.  44:1057-1064. 2009
    2009 Experience of the school-aged child with tracheostomy.  International Journal of Pediatric Otorhinolaryngology.  73:975-980. 2009
    2009 Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis.  Pediatric Pulmonology.  44:503-511. 2009
    2006 Physiologic, bronchoscopic, and bronchoalveolar lavage fluid findings in young children with recurrent wheeze and cough.  Pediatric Pulmonology.  41:709-719. 2006

    Research Overview

  • Cystic Fibrosis, Pediatric Lung Disease, TGF-beta signaling, Airway Remodeling, miRNA

    • Principal Investigator On

  • Bronchoalveolar Lavage Fluid (BALF) Specimen Bank and Lower Airway Microbiome Analysis in Children and Adults With and Without Cystic Fibrosis (CF)  awarded by University of Colorado
  • Effect of Vitamin D Deficiency on Murine Lung Development and Function  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Losartan as Anti-Inflammatory Therapy to Augment F508del CFTR Recovery  awarded by University of Miami
  • Mechanisms of Pulmonary Fibrosis in CF Lung Disease  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • MiR-145 Mediated TGF-Beta Pathobiology in CF  awarded by Cystic Fibrosis Foundation ^
  • Myofibroblast Differentiation in Cystic Fibrosis  awarded by Cystic Fibrosis Foundation ^
  • Myofibroblast Proliferation in Cystic Fibrosis: A Novel Mechanism of Disease Modification  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Oligotherapeutics to Enhance CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Overcoming Barriers to F508del CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • miR-145 Inhibition: A Novel Strategy to Improve CFTR Therapeutics  awarded by Cystic Fibrosis Foundation ^
  • miR-145 Target Site Blockade is a Selective Strategy to Enhance CFTR Restoration and Readthrough  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • miR-145 Target Site Blockade to Amplify CFTR Correction  awarded by Cystic Fibrosis Foundation ^

    • Investigator On

  • Pediatric Physician Training in Translational Research  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • Prevalence and Significance of Staphylococcus Aureus Small–Colony Variants  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by GRIFOLS, INC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PROQR THERAPEUTICS
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • The Genetic Contribution to Drug Induced Renal lnjury:The Drug Induced Renal Injury Consortium (DIRECT)  awarded by INTERNATIONAL SAE CONSORTIOUM, LTD
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation ^

    • Education And Training

  • Johns Hopkins Hospital, Residency
  • University of North Carolina Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Southwestern University 1999
  • Bachelor of Engineering in Materials Engineering, Rice University 1994

    • Full Name

  • William Harris